Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.

Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Abstract Text:

    k amarasingheK Amarasinghe,c dalleyC Dalley,i dokalI Dokal,a laurieA Laurie,v guptaV Gupta,j marshJ Marsh,k amarasingheK Amarasinghe,c dalleyC Dalley,i dokalI Dokal,a laurieA Laurie,v guptaV Gupta,j marshJ Marsh,

    Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Publishing Authors By Initials

    k amarasingheK Amarasinghe,c dalleyC Dalley,i dokalI Dokal,a laurieA Laurie,v guptaV Gupta,j marshJ Marsh,k amarasingheK Amarasinghe,c dalleyC Dalley,i dokalI Dokal,a laurieA Laurie,v guptaV Gupta,j marshJ Marsh,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Journal Published:

    PUBLICATION TYPE: Letter

    Journal: Bone marrow transplantation

    VOLUME: 40

    Page Numbers: 913-4

    Journal Abbreviation: Bone Marrow Transplant.

    ISSN: 0268-3369

    DAY: 27

    MONTH: 08

    YEAR: 2007

    Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8702459

    Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.

    AFFILIATION:

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Bone Marrow Transplant

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News